Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
4.280
-0.300 (-6.55%)
Oct 6, 2026, 4:00 PM EDT - Market closed
Myriad Genetics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Myriad Genetics stock has a consensus rating of "Hold" and an average price target of $3.91. The average 1-year stock price forecast is 8.64% lower than the current stock price, while the lowest is $2.00 (-53.27%) and the highest is $8.00 (+86.92%).
Price Target: $3.91 (-8.64%)
Analyst Consensus: Hold
Price Target
ChartAnalyst Ratings
The average analyst rating for Myriad Genetics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 6 | 5 | 4 | 5 | 5 | 5 |
| Sell | 1 | 1 | 1 | 1 | 2 | 2 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 10 | 9 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Buy Maintains $4 → $8 | Buy | Maintains | $4 → $8 | +86.92% | Oct 2, 2026 |
Unknown Analyst UBS No rating | UBS | Hold Initiates $6 → $3.6 | Hold | Initiates | $6 → $3.6 | -15.89% | Sep 9, 2026 |
| Piper Sandler | Piper Sandler | Sell Downgrades $8.5 → $2 | Sell | Downgrades | $8.5 → $2 | -53.27% | Sep 1, 2026 |
Unknown Analyst Jefferies No rating | Jefferies | Sell Maintains $2.5 | Sell | Maintains | $2.5 | -41.59% | Aug 21, 2026 |
| Stephens | Stephens | Hold Reiterates $3 | Hold | Reiterates | $3 | -29.91% | Aug 18, 2026 |
Financial Forecast
Revenue This Year
777.92M
from 824.50M
Decreased by -5.65%
Revenue Next Year
820.95M
from 777.92M
Increased by 5.53%
EPS This Year
-0.74
from 0.06
EPS Next Year
-0.58
from -0.74
EPS and Forward PE are based on non-GAAP adjusted numbers.